At the World Glaucoma Congress (WGC) in Rome, Italy this summer, Ciliatech presented preliminary results of the second 2-year postoperative clinical trial (SAFARI Ⅱ) on its Cilioscleral Interposition Device (CID).
Glaucoma is a group of progressive, neurodegenerative eye diseases associated with irreversible optic neuropathy followed by visual-field impairment. Epidemiological estimates suggest that the most common form,
Ciliatech reports positive clinical results on novel glaucoma implant, CID, in 24-month post-operative
follow-up. Data support sustained safety and performance of first generation glaucoma implant CID (Cilio-scleral Interpositioning Device)...